Find Clinical Trial
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects with Nonresectable or Metastatic IDH1-Mutant Cholangiocarcinoma
← Back
| Study Phase |
Phase 1-2 |
| Therapeutic Area |
Cancers |
| Indication | Second- or third-line treatment of IDH1-mutant cholangiocarcinoma |
| Sponsor | Servier Bio-Innovation LLC |
| Active substance/ Medical device |
Ivosidenib |
| Active Substance Code | S95031 |
| Protocol Code | CL1-95031-006 |
| Eu CT | 2023-503236-41-00 |
| NCT Code | NCT05921760 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2025 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
